BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran as CEO and Idan Elmelech as COO
Position
Chief Operating Officer
Company
BridgeBio Oncology Therapeutics
South San FranciscoBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
BridgeBio Oncology Therapeutics, Inc. announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026
Quick answer
BridgeBio Oncology Therapeutics Appoints Pedro J. Beltran as CEO and Idan Elmelech as COO (April 22, 2026). BridgeBio Oncology Therapeutics is based in South San Francisco, California, United States.
- Who is the new Chief Operating Officer at BridgeBio Oncology Therapeutics?
- BridgeBio Oncology Therapeutics named Idan Elmelech Chief Operating Officer, announced April 22, 2026.
- What did BridgeBio Oncology Therapeutics announce on April 22, 2026?
- BridgeBio Oncology Therapeutics, Inc. announced the appointment of Pedro J. Beltran, PhD, as Chief Executive Officer and Idan Elmelech as Chief Operating Officer effective April 20th, 2026
- What does BridgeBio Oncology Therapeutics do?
- BridgeBio Oncology Therapeutics, a clinical-stage biopharmaceutical company, focuses on RAS-pathway malignancies, specifically developing therapies for patients with KRASG12C mutations.
- Where is BridgeBio Oncology Therapeutics based?
- BridgeBio Oncology Therapeutics is based in South San Francisco, California, United States.
- Which similar companies made leadership changes around the same time?
- NRx Pharmaceuticals (April 13, 2026), Abivax (April 12, 2026), TORL BioTherapeutics (May 7, 2026) and Minerva Neurosciences (April 2, 2026) also announced leadership changes within 45 days of BridgeBio Oncology Therapeutics.
Source: Fundz verified event record.
Other recent leadership changes in Therapeutics and Pharmaceutical
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- NRx Pharmaceuticals Appoints Glenn Tyson as Chief Commercial Officer (April 13, 2026)
- ABIVAX Appoints Michael Nesrallah as Chief Commercial Officer (April 12, 2026)
- TORL BioTherapeutics Appoints Aran Maree, M.D., as Chief Executive Officer (May 7, 2026)
- Minerva Neurosciences Appoints Dr. Sheila O’Connor as President and CEO (April 2, 2026)
- Vanda Pharmaceuticals Inc. Announces Resignation of Senior Executive (April 2, 2026)
- OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer (May 14, 2026)
Who to call at BridgeBio Oncology Therapeutics, and when
A new leader at BridgeBio Oncology Therapeutics brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day BridgeBio Oncology Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BridgeBio Oncology Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BridgeBio Oncology Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BridgeBio Oncology Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
BridgeBio Oncology Therapeutics changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.